Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator ...

TransCon Growth Hormone or TransCon hGH is now approved in the US by the FDA for the replacement of endogenous growth hormone ...

Bioxytran has reported positive results from its completed phase 2 trial of ProLectin‑M, showing rapid and sustained viral clearance in subjects with laboratory‑confirmed acute viral infection. The ...

The Wall Street Journal editorial board published a scathing takedown on Wednesday of President Donald Trump's top Food and ...

February 2026 is shaping up to be a monumental month for Xbox enthusiasts, with a diverse slate of titles arriving on both ...

Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 February 11, 2026 6:30 ...

DARE to PLAY™ represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical ...

For most implants and other high-risk devices brought to market, manufacturers do nothing more than file some paperwork and ...

Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast ...

What if you could design a system that completely severs the link between losing and draft position? Here's an idea.

Artificial intelligence (AI) is rapidly reshaping how software is built, and increasingly, how it’s taught. At the 2026 ...